	-			
Oregon Health & Science University Hospital and Clinics Provider's Orders				
	ACCOUNT NO.			
	MED. REC. NO.			
OHSU ^Q	NAME			
	BIRTHDATE			
ADULT AMBULATORY INFUSION ORDER				
Ocrelizumab (OCREVUS) Infusion				
Page 1 of 3	Patient Identification			
ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.				
Weight:kg Height:	cm			
Allergies:				
Diagnosis Code:				

This plan will expire after 365 days at which time a new order will need to be placed

Treatment Start Date: _____ Patient to follow up with provider on date: ____

** Height, weight, and BSA are required for a complete order**

Scheduling instructions: Initial dose 300 mg, intravenous, x 2 doses, 14 days apart. Maintenance dose 600 mg, intravenous, starting 6 months after initial dose, every 6 months.

GUIDELINES FOR ORDERING

- 1. Send FACE SHEET and H&P or most recent chart note.
- 2. Hepatitis B (Hep B surface antigen and core antibody total) screening must be completed prior to initiation of treatment and the patient should not be infected. Please send results with order.

PRE-SCREENING: (Results must be available prior to initiation of therapy):

□ Hepatitis B surface antigen and core antibody test results scanned with orders

NURSING ORDERS:

- 1. TREATMENT PARAMETER Hold treatment and contact provider if Hepatitis B surface antigen or core antibody total test result is positive or if screening has not been performed.
- 2. RN to assess for active infection. If patient shows signs and symptoms of active infection or currently taking antibiotics. Hold treatment and notify provider
- 3. VITAL SIGNS First and second infusions: Obtain vital signs at baseline, then every 30 minutes with rate escalation, then every 30 minutes for the duration of the infusion. Third infusion and beyond: Obtain vital signs at baseline, then every 30 minutes with rate escalation. If no previous infusion reaction, monitor vital signs every hour until infusion complete.
- 4. Monitor patient for Ocrelizumab infusion-related reactions for 1 hour after completion of first and second Ocrelizumab infusions. Monitoring not required for third infusion and beyond, if no previous infusion reactions. Lengthened monitoring recommended for previous infusion reactions, contact provider for guidance
- 5. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes


PRE-MEDICATIONS: (Administer 30-60 minutes prior to infusion)

Note to provider: Please select which medications below, if any, you would like the patient to receive prior to treatment by checking the appropriate box(s)

- acetaminophen (TYLENOL) tablet, 650 mg, oral, ONCE, every visit
- □ diphenhydrAMINE (BENADRYL) capsule, 50 mg, oral, ONCE, every visit. Give either loratadine or diphenhydrAMINE, not both.
- □ loratadine (CLARITIN) tablet, 10 mg, oral, ONCE AS NEEDED if diphenhydrAMINE is not given, every visit. Give either loratadine or diphenhydrAMINE, not both.
- □ methylPREDNISolone sodium succinate (SOLU-MEDROL), 100 mg, intravenous, ONCE, every visit

ONLINE 07/2021 [supersedes 04/2021]

PO-8108



ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

Monoclonal Antibody:

□ Ocrelizumab (OCREVUS) 300 mg in sodium chloride 0.9%, intravenous

Every 2 weeks for 2 treatments

Infuse per infusion plan nursing orders. Infuse through 0.2 micron inline filter. Do not shake

NURSING COMMUNICATION – For 300 mg infusions: Infuse Ocrelizumab via pump slowly at 30 mL/hr for the first half-hour. If no infusion related side effect is seen, increase rate gradually (30 mL/hour) every 30 minutes to a maximum of 180 mL/hour. If infusion not tolerated, STOP infusion, notify provider and administer appropriate hypersensitivity medications. When infusion related side effects have resolved begin the Ocrelizumab infusion at half the previous rate. Resume titrations with provider guidance

□ Ocrelizumab (OCREVUS) 600 mg in sodium chloride 0.9%, intravenous

Every 24 weeks, until discontinued

Infuse per infusion plan nursing orders. Infuse through 0.2 micron inline filter. Do not shake

NURSING COMMUNICATION – For 600 mg infusions: If previous infusion reaction, contact provider for rate guidance. If no previous infusion related side effects noted, infuse Ocrelizumab via pump at 100 mL/hr for the first 15 minutes. Increase to 200 mL/hr for the next 15 minutes. Increase to 250 mL/hr for the next 30 minutes. Increase to 300 mL/hr for the remaining 60 minutes. If infusion not tolerated STOP infusion, notify provider and administer appropriate hypersensitivity medications. When infusion related side effects have resolved begin the Ocrelizumab infusion at half the previous rate.

HYPERSENSITIVITY MEDICATIONS:

- If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (Policy HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
- 2. acetaminophen (TYLENOL) tablet, 650 mg, oral, EVERY 4 HOURS AS NEEDED for infusion reaction
- 3. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x1 dose for rash, hypersensitivity or infusion reaction
- 4. EPINEPHrine HCI (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x1 dose for hypersensitivity reaction
- 5. famotidine (PEPCID) IV, 20 mg, intravenous, AS NEEDED x1 dose for hypersensitivity or infusion reaction
- hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x1 dose for hypersensitivity or infusion reaction
- 7. meperidine (DEMOEROL) injection, 25-50 mg, intravenous, every 2 hours as needed for infusionrelated severe rigors in the absence of hypotension. Not to exceed 50 mg/hr
- 8. sodium chloride 0.9% IV bolus, 1,000 mL, as needed for infusion related side effects

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE. By signing below, I represent the following:				
		Defined Idea (files files		
	Page 3 of 3	BIRTHDATE		
OHSU	Ocrelizumab (OCREVUS) Infusion	NAME		
	ADULT AMBULATORY INFUSION ORDER	MED. REC. NO.		
(\mathbf{X})		ACCOUNT NO.		
	Oregon Health & Science University Hospital and Clinics Provider's Orders			

I hold an active, unrestricted license to practice medicine in: \Box Oregon \Box (check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon);

My physician license Number is # <u>(MUST BE COMPLETED TO BE A VALID</u> <u>PRESCRIPTION</u>; and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

Provider signature:	Date/Time:	
Printed Name:	Phone:	Fax:

Please check the appropriate box for the patient's preferred clinic location:



OHSUHealth Hillsboro Medical Center FORMERLY TUALITY HEALTHCARE

Infusion Services 364 SE 8th Ave, Medical Plaza Suite 108B Hillsboro, OR 97123 Phone number: (503) 681-4124 Fax number: (503) 681-4120



Celilo Cancer Center 1800 E 19th St The Dalles, OR 97058 Phone number: (541) 296-7585 Fax number: (541) 296-7610